Skip to main content

Table 6 Persistence in post-index period in the male LUTS (including OAB) sub-cohort

From: The use of mono- and combination drug therapy in men and women with lower urinary tract symptoms (LUTS) in the UK: a retrospective observational study

Index drug N Persistence days Median (Q1–Q3)
Monotherapy   
Solifenacin 2759 97 (30–365a)
Oxybutynin 2613 56 (28–363)
Tolterodine 1445 56 (28–359)
Mirabegron 503 205 (50–365a)
Fesoterodine 285 115 (28–365a)
Trospium 227 102 (30–365a)
Flavoxate 49 54 (30–222)
Darifenacin 47 71 (28–365a)
Propiverine 18 42 (28–273)
Combination drug therapy   
Solifenacin + tamsulosin 902 111 (53–365a)
Oxybutynin + tamsulosin 364 65 (42–195)
Tamsulosin + tolterodine 248 99 (48–335.5)
Finasteride + solifenacin + tamsulosin 233 121 (61–365a)
Doxazosin + solifenacin 114 117 (59–308)
Solifenacin + tolterodine 114 50 (34–75)
Finasteride + oxybutynin + tamsulosin 111 69 (49–215)
Oxybutynin + solifenacin 102 54 (38–82)
Finasteride + solifenacin 96 120 (55–365a)
Mirabegron + tamsulosin 96 98 (47–365a)
Doxazosin + oxybutynin 95 60 (44–128)
Mirabegron + solifenacin 95 61 (42–95)
Fesoterodine + tamsulosin 83 80 (50–221)
Dutasteride + solifenacin + tamsulosin 79 74 (51–235)
Doxazosin + tolterodine 69 95 (50–365a)
Tamsulosin + trospium 65 144 (61–365a)
Finasteride + oxybutynin 62 77 (42–240)
Finasteride + tamsulosin + tolterodine 57 119 (62–365a)
Alfuzosin + solifenacin 47 124 (42–365a)
Other combinations 1405 63 (41–151)
  1. LUTS: lower urinary tract symptoms; OAB: overactive bladder; Q1: lower quartile; Q3: upper quartile
  2. aQ3 not reached by 365 days